Leading the pharmacogenetics market
Align with the guidelines
CYP2C19 genotyping to guide dual antiplatelet therapy decision making, is now included in the new AHA/ASA guideline for Early Management of Patients with Acute Ischemic Stroke
Same Treatment
Different People
Different Results
Every person, including you, carries genetic variations that influence how your body functions. These variations are a natural part of human biology and play a fundamental role in your health, disease risk, and how you respond to medical treatment.
With these variations, the same therapy may work well for someone else but may not work for you. By understanding your genetic profile, a clinician can make more informed treatment decisions, tailored specifically to you.
Pharmacogenetics Enables Healthcare Providers To Make Informed Therapeutic Decisions¹
Studies indicate that more than 98% of individuals may have a genomic variant that could affect how they respond to commonly prescribed medications.¹
Specific genes are required for drug metabolism.
Pharmacogenetics (PGx) can be used to identify different therapeutic targets
Specific genes can predict severe reactions to certain types of medications
Critical proteins for transport of medications are encoded by genes. Variants of the gene can cause slower transport which can cause drugs to build-up and become toxic
Advanced Genotyping Capabilities
in a compact platform
Genomadix enables rapid point-of-need genetics testing to support clinicians in making effective therapy decisions in acute settings.
Genomadix is a pioneer in real-time qPCR point of need technology.
The Genomadix Cube is a molecular diagnostic instrument capable of performing tests for precision medicine genotyping on a sample-to-result platform. The portable size, ease of use, and on-demand processing capability enables users to generate time-critical results in approximately one hour.
No blood draw. No pain.
The Genomadix cheek swab gently collects cells from the inside of a patient’s cheek, which contains the DNA required for testing.
Testing Simplicity
Each Test Cartridge contains all the material needed to conduct direct PCR on the cheek swab sample.
CYP2C19 is a gene that tells your body how to make an enzyme that is involved in the metabolism (either elimination or activation) of 10% of all drugs on the market. These drugs are used to treat neurological conditions, fungal infections, gastric conditions, and cardiac conditions.
Approximately 30% of patients in North America and Europe have one or more Loss of Function (LOF) variants in their CYP2C19 genes, which affects how quickly they either activate or eliminate these drugs.
Our focus today is addressing the acute need for CYP2C19 genotyping
Of the approximately 4 million people prescribed clopidogrel (Plavix®) each year, about 30% or 1.2 million people may not receive the therapeutic benefit as a result of their genetics.¹,²
One of the drugs metabolized by CYP2C19, clopidogrel, is an antiplatelet therapy used to prevent blood clots in patients who have had a minor stroke, transient ischemic attack (TIA) or had a stent placed.
The FDA has issued a black box warning (the highest level of warning) for clopidogrel, to warn of the diminished effects of the drug in patients with Loss of Function alleles.
Clinical guidelines recommend testing patients to identify if they carry variations in the CYP2C19 gene that prevent them from effectively metabolizing Clopidogrel.¹,³
In stroke and acute coronary syndrome,
getting on the right antiplatelet medication quickly is essential.
- Patients with minor ischemic stroke or transient ischemic attack (TIA) are at high risk of a second stroke, and almost half of those second strokes occur within 48 hours of the first stroke⁴
- Patients with acute coronary syndrome (heart attack or unstable angina) often receive a stent to restore blood flow, but these patients are also at high risk of secondary heart attacks, strokes, or bleeding events⁵
- In a large randomized controlled trial called CHANCE-2, it was demonstrated that treating patients with a minor stroke or TIA who are CYP2C19 LOF carriers with ticagrelor rather than clopidogrel resulted in a 21% reduction in secondary strokes in the first 90 days⁶
- In a large randomized controlled trial called POPular Genetics, it was shown that acute coronary syndrome patients receiving a stent had a 22% reduction in bleeding events when they were prescribed CYP2C19 genotype-guided antiplatelet treatment as compared to the standard of care ticagrelor or prasugrel7
Precision Medicine is Better Medicine
But there’s a problem.......
traditional CYP2C19 testing takes 5-7 days for results.
And doctors need to act fast to get their patients on the right medication, tailored to them.
Using the Genomadix Cube CYP2C19 test allows clinicians to have the answer they need, when they need it, to make sure each of their patients is on the right medication from the start.
References:
Lee CR, et al. J Clinical Pharmacol Therapeutics. 2022;122(5):959-967
https://clincalc.com/DrugStats/Drugs/Clopidogrel. Accessed February 5, 2026
Prabhakaran S. et al. Stroke. 2026.
Johnston et al., JAMA 2020; 284: 2901-2906.
Giustino, G. et al., JACC. 2017;70(15):1846-1857.
Wang Y, et al. N Engl J Med. 2021;385:2520-2530.
- Claassens DMF et al. N Engl J Med 2019;381:1621-1631.
Align with the guidelines
CYP2C19 genotyping to guide dual antiplatelet therapy decision making, is now included in the new AHA/ASA guideline for Early Management of Patients with Acute Ischemic Stroke
